Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DanaherXSWX:DHR 79 Days Sales Outstanding is 57.74 as of Jun. 2026, which is 7% below its 10-year median of 62.35. GuruFocus rates XSWX:DHR with a GF Score™ of 79/100 and a GF Value™ of CHF199.29. The stock has 5 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Danaher ranks better than 62.69% on this metric.
Danaher's average Accounts Receivable for the
three
months ended in Jun. 2026 was CHF3,134 Mil. Danaher's Revenue for the
three
months ended in Jun. 2026 was CHF4,952 Mil.
Hence, Danaher's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 57.74.
The historical rank and industry rank for Danaher's Days Sales Outstanding or its related term are showing as below:
XSWX:DHR'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.29 Med: 62.35 Max: 78.88
Current: 55.29
During the past 13 years, Danaher's highest Days Sales Outstanding was 78.88. The lowest was 55.29. And the median was 62.35.
XSWX:DHR's Days Sales Outstanding is ranked better than 62.69% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs XSWX:DHR: 55.29
Danaher's Days Sales Outstanding
increased
from Jun. 2025 (55.21) to Jun. 2026 (57.74).
Danaher (XSWX:DHR) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Danaher Days Sales Outstanding Related Terms
Danaher Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Danaher's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:DHR vs TMO, NTRA, IDXX: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Danaher's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Danaher Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Danaher's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Danaher (XSWX:DHR) has a Days Sales Outstanding of 57.74 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Danaher and its competitors. This is near median its historical median of 62.35. Over the past decade, Danaher's Days Sales Outstanding has ranged from 55.29 to 78.88. According to the industry distribution chart, Danaher ranks #75 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 37.3%.
Is Danaher's Days Sales Outstanding too high?
Danaher's current Days Sales Outstanding of 57.74 is near median its 10-year median of 62.35. Over the past 10 years, this metric has ranged from a low of 55.29 to a high of 78.88. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. Danaher's value of 57.74 is 14.6% below this industry median. Based on the distribution chart, Danaher ranks #75 out of 201 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Danaher has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Danaher's Days Sales Outstanding compare to TMO and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, Danaher ranks #75 out of 201 companies for Days Sales Outstanding. This puts Danaher in the upper half of its industry. The industry median Days Sales Outstanding is 67.59. Danaher's value of 57.74 is 14.6% below this benchmark. Historically, Danaher's own Days Sales Outstanding has ranged from 55.29 to 78.88 over the past decade. While the company's 10-year median is 62.35 vs. the industry median of 67.59, Danaher has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Danaher's current Days Sales Outstanding of 57.74 is 14.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Danaher and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Danaher's current Days Sales Outstanding is 57.74, which is near median its own 10-year median of 62.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danaher stock overvalued right now?
Danaher (XSWX:DHR) has a current Days Sales Outstanding of 57.74. The stock's GF Value™ is CHF199.29, compared to a current price of CHF173.42 — trading 13% below its estimated fair value. The current Days Sales Outstanding is 57.74, which is near median its 10-year median of 62.35 and 14.6% below the Medical Diagnostics & Research industry median of 67.59. Danaher's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Danaher (XSWX:DHR), the current Days Sales Outstanding is 57.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Danaher (XSWX:DHR) Overvalued in 2026?
Based on GuruFocus' analysis, Danaher stock appears to be undervalued.
The current stock price of CHF173.42 is trading 13% below its estimated GF Value™ of CHF199.29.
Key valuation signals for XSWX:DHR:
Days Sales Outstanding: 57.74 (near median its 10-year median of 62.35)
GF Value™: CHF199.29 vs. price of CHF173.42 (13% below fair value)
Industry Position: 14.6% below the Medical Diagnostics & Research median (#75 of 201)
No single metric tells the full story. See the XSWX:DHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
79GF Score
Get the complete analysis for XSWX:DHR
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DHR has been successfully added to your 
